Evidence map›Paper›PMID 29502191›Full record

ArticleGlycoconjugate journal2018

The glycomic effect of N-acetylglucosaminyltransferase III overexpression in metastatic melanoma cells. GnT-III modifies highly branched N-glycans.

Paweł Link-Lenczowski, Monika Bubka, Crina I A Balog, Carolien A M Koeleman, Terry D Butters, Manfred Wuhrer, Anna Lityńska

Open access · hybridAbstract read
In one paragraph

Article in Glycoconjugate journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Changes of IgGFrontiers in immunology · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Paweł Link-LenczowskiDepartment of Medical Physiology, Faculty of Health Sciences, Jagiellonian University Medical College, Michałowskiego 12, 31-126, Kraków, Poland. p.link-lenczowski@uj.edu.pl.ORCID http://orcid.org/0000-0002-0084-775X
Monika BubkaDepartment of Glycoconjugate Biochemistry, Institute of Zoology and Biomedical Research, Jagiellonian University, Kraków, Poland.
Crina I A BalogCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Carolien A M KoelemanCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Terry D ButtersOxford Glycobiology Institute, Oxford, UK.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Anna LityńskaDepartment of Glycoconjugate Biochemistry, Institute of Zoology and Biomedical Research, Jagiellonian University, Kraków, Poland.
Jagiellonian University · PLLeiden University Medical Center · NL

Funding

Narodowe Centrum Nauki 3046/B/P01/2009/37
6 · The paper itself

Abstract

N-acetylglucosaminyltransferase III (GnT-III) is known to catalyze N-glycan "bisection" and thereby modulate the formation of highly branched complex structures within the Golgi apparatus. While active, it inhibits the action of other GlcNAc transferases such as GnT-IV and GnT-V. Moreover, GnT-III is considered as an inhibitor of the metastatic potential of cancer cells both in vitro and in vivo. However, the effects of GnT-III may be more diverse and depend on the cellular context. We describe the detailed glycomic analysis of the effect of GnT-III overexpression in WM266-4-GnT-III metastatic melanoma cells. We used MALDI-TOF and ESI-ion-trap-MS/MS together with HILIC-HPLC of 2-AA labeled N-glycans to study the N-glycome of membrane-attached and secreted proteins. We found that the overexpression of GnT-III in melanoma leads to the modification of a broad range of N-glycan types by the introduction of the "bisecting" GlcNAc residue with highly branched complex structures among them. The presence of these unusual complex N-glycans resulted in stronger interactions of cellular glycoproteins with the PHA-L. Based on the data presented here we conclude that elevated activity of GnT-III in cancer cells does not necessarily lead to a total abrogation of the formation of highly branched glycans. In addition, the modification of pre-existing N-glycans by the introduction of "bisecting" GlcNAc can modulate their capacity to interact with carbohydrate-binding proteins such as plant lectins. Our results suggest further studies on the biological function of "bisected" oligosaccharides in cancer cell biology and their interactions with carbohydrate-binding proteins.

Indexed as

Cell Line, TumorHumansMelanomaN-AcetylglucosaminyltransferasesPolysaccharidesbeta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferaseN-AcetylglucosaminyltransferasesPolysaccharidesCancerGlycomeGlycosylationMelanomaN-acetylglucosaminyltransferase III

Identifiers

PMID29502191
PMCPMC5916991
OpenAlexW2790868150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.